Survival analysis of HER2 receptor negative and HER2 receptor low breast cancer patients at a Philippine hospital

被引：0
|
作者：
Arenos, C. C. [1 ]
San Juan, M. [1 ]
Lim, S. [1 ]
Lominoque, A. [1 ]
Reveldez, I. [1 ]
Sison-DImaano, A. [1 ]
Pangandaman, N. [1 ]
Tatoy, V. [1 ]
Uy, T. [1 ]
机构：
[1] Univ Philippines, Div Med Oncol, Dept Med, Philippine Gen Hosp, Manila, Philippines
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.07.460
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P85-2
引用
收藏
页码：S1390 / S1390
页数：1
相关论文
共 50 条
  • [1] Survival analysis of HER2 receptor negative and HER2 receptor low breast cancer patients at a Philippine Tertiary Government Hospital
    Arenos, Carl
    Lim, Steven
    Lominoque, Andreu
    Reveldez, Isabela
    Sison-Dimaano, Angeli
    Pagandaman, Nehar
    Tatoy, Vincent
    Uy, Timothy
    San Juan, Michael
    ECANCERMEDICALSCIENCE, 2025, 19
  • [2] IMPACT OF HORMONE RECEPTOR STATUS AND HER2 ON SURVIVAL OF TRIPLE NEGATIVE BREAST CANCER PATIENTS
    Xiao, H.
    Tan, F.
    Huang, Y.
    Feldman, J.
    Koniaris, L.
    Gummadi, S.
    Adunlin, G. B.
    Ali, A. A.
    VALUE IN HEALTH, 2013, 16 (03) : A131 - A131
  • [3] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
    Chen, Zhaoxu
    Jia, Huiqing
    Zhang, Huina
    Chen, Lifang
    Zhao, Peng
    Zhao, Jing
    Fu, Guangming
    Xing, Xiaoming
    Li, Yujun
    Wang, Chengqin
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (02) : 313 - 323
  • [4] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
    Zhaoxu Chen
    Huiqing Jia
    Huina Zhang
    Lifang Chen
    Peng Zhao
    Jing Zhao
    Guangming Fu
    Xiaoming Xing
    Yujun Li
    Chengqin Wang
    Breast Cancer Research and Treatment, 2023, 202 : 313 - 323
  • [5] Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer
    Mattos, Bruna RaphaeliSilva
    Cesca, Marcelle Goldner
    Leite, Luciana de Moura
    Tavares, Monique Celeste
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla AlbinaZanco
    Silva, Erick Figueiredo
    Rocha, Francisca Giselle
    Loose, Simone Klug
    Campos, Fernando AugustoBatista
    Sanches, Solange Moraes
    de Lima, Vladmir ClaudioCordeiro
    Ponde, Noam Falbel
    CANCER RESEARCH, 2021, 81 (04)
  • [6] The Survival Benefit of Endocrine Therapy in Low Estrogen Receptor Positive/HER2 Negative Invasive Breast Cancer
    Alhamar, Mohamed
    Alkamachi, Bassam
    Mehrotra, Harshita
    Ohan, Hovsep
    Ali, Haythem
    Gupta, Nilesh
    Hassan, Oudai
    Chitale, Dhananjay
    Schultz, Daniel
    Allo, Ghassan
    Alkhoory, Wamidh
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 74 - 76
  • [7] The Survival Benefit of Endocrine Therapy in Low Estrogen Receptor Positive/HER2 Negative Invasive Breast Cancer
    Alhamar, Mohamed
    Alkamachi, Bassam
    Mehrotra, Harshita
    Ohan, Hovsep
    Ali, Haythem
    Gupta, Nilesh
    Hassan, Oudai
    Chitale, Dhananjay
    Schultz, Daniel
    Allo, Ghassan
    Alkhoory, Wamidh
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 74 - 76
  • [8] Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance
    Emde, Anna
    Mahlknecht, Georg
    Maslak, Kerstin
    Ribba, Benjamin
    Sela, Michael
    Possinger, Kurt
    Yarden, Yosef
    TRANSLATIONAL ONCOLOGY, 2011, 4 (05): : 293 - 300
  • [9] IGF2 activation of HER2 receptor in HER2 positive breast cancer cell lines
    Helu, Xousaen M.
    De Leon, Daisy D.
    CANCER RESEARCH, 2012, 72
  • [10] Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
    Laidi, Fatna
    Bouziane, Amal
    Lakhdar, Amina
    Khabouze, Samira
    Rhrab, Brahim
    Zaoui, Fatima
    ONCOTARGETS AND THERAPY, 2014, 7 : 1285 - 1289
12345